Telix Pharmaceuticals Limited (TLX)Healthcare | Biotechnology | North Melbourne, Australia | NasdaqGS
11.29 USD
-0.09
(-0.747%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 11.29 |
Hot Take ↕ | Aug. 22, 2026, 4:58 a.m. EDT
The immediate outlook is mixed due to conflicting signals. On one hand, the stock has rallied significantly over the last two months, trading well above its 50-day and 200-day moving averages, suggesting strong recent momentum driven by the Regeneron deal and earnings beat. However, the statistical forecasting model indicates a flat predicted direction with low confidence, warning that this recent pop may be noise rather than a sustainable trend. This creates a neutral stance for the near term: while the technicals look attractive, the lack of a clear statistical edge prevents a bullish call. Looking further ahead, the investment case remains neutral despite the hype. The company is a biotech innovator with impressive top-line growth (22.3%) and a recent major partnership, which supports the business thesis. Yet, the financials tell a cautionary tale: the stock trades at a massive 126x trailing P/E and 78x forward P/E, implying extremely high expectations that leave little room for error. Furthermore, the balance sheet is strained with debt-to-equity exceeding 118% and negative free cash flow, forcing the company to refinance convertible bonds. These structural weaknesses prevent a 'buy' rating, capping the long-term view at neutral despite the promising product pipeline. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.099884 |
| AutoARIMA | 0.099885 |
| MSTL | 0.104000 |
| AutoTheta | 0.126505 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 36% |
| H-stat | 8.39 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.446 |
| Excess Kurtosis | -0.88 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 118.903 |
| Revenue per Share | 2.606 |
| Market Cap | 3,824,792,832 |
| Trailing P/E | 112.90 |
| Forward P/E | 77.45 |
| Beta | 0.60 |
| Profit Margins | 3.76% |
| Website | https://telixpharma.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 0.19724286 |
| Address1 | 55 Flemington Road |
| Address2 | Level 4 |
| All Time High | 30.36 |
| All Time Low | 6.28 |
| Ask | 10.32 |
| Ask Size | 1 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 150,780 |
| Average Daily Volume3 Month | 163,777 |
| Average Volume | 163,777 |
| Average Volume10Days | 150,780 |
| Beta | 0.6 |
| Bid | 11.27 |
| Bid Size | 1 |
| Book Value | 1.226 |
| City | North Melbourne |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | Australia |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 11.29 |
| Current Ratio | 2.014 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 11.47 |
| Day Low | 11.2066 |
| Debt To Equity | 118.903 |
| Display Name | Telix Pharmaceuticals |
| Earnings Call Timestamp End | 1,740,088,800 |
| Earnings Call Timestamp Start | 1,740,088,800 |
| Earnings Timestamp End | 1,756,123,200 |
| Earnings Timestamp Start | 1,755,687,540 |
| Ebitda | 69,806,000 |
| Ebitda Margins | 0.07836 |
| Enterprise To Ebitda | 59.653 |
| Enterprise To Revenue | 4.675 |
| Enterprise Value | 4,164,115,712 |
| Eps Current Year | 0.1542 |
| Eps Forward | 0.14577024 |
| Eps Trailing Twelve Months | 0.1 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 11.0867 |
| Fifty Day Average Change | 0.20329952 |
| Fifty Day Average Change Percent | 0.018337242 |
| Fifty Two Week Change Percent | 19.724285 |
| Fifty Two Week High | 12.48 |
| Fifty Two Week High Change | -1.1899996 |
| Fifty Two Week High Change Percent | -0.09535253 |
| Fifty Two Week Low | 6.28 |
| Fifty Two Week Low Change | 5.0099998 |
| Fifty Two Week Low Change Percent | 0.7977706 |
| Fifty Two Week Range | 6.28 - 12.48 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,731,594,600,000 |
| Float Shares | 273,621,496 |
| Forward Eps | 0.14577024 |
| Forward P E | 77.45065 |
| Free Cashflow | -62,596,000 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 1,120 |
| Fullday Change | -0.085 |
| Fullday Change Percent | -0.747253 |
| Fullday Price | 11.29 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.47566003 |
| Gross Profits | 423,707,008 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0 |
| Held Percent Institutions | 0.00981 |
| Implied Shares Outstanding | 338,777,049 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,024-11-13 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing BiPASS, which is in Phase 3 clinical trial for prostate cancer diagnosis; AlFluor, a novel PET radiochemistry solution; TLX250-Px, a PET diagnostic imaging agent; and TLX101-Px, a radiolabeled amino acid PET agent. It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company has strategic collaboration with University Hospital Essen. The company was founded in 2015 and is headquartered in North Melbourne, Australia. |
| Long Name | Telix Pharmaceuticals Limited |
| Market | us_market |
| Market Cap | 3,824,792,832 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_537247297 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | 33,497,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 3,801,401,477 |
| Number Of Analyst Opinions | 4 |
| Open | 11.47 |
| Operating Cashflow | -12,006,000 |
| Operating Margins | 0.09712 |
| Payout Ratio | 0.0 |
| Phone | 61 3 9093 3855 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 11.29 |
| Post Market Time | 1,787,959,806 |
| Previous Close | 11.375 |
| Price Eps Current Year | 73.2166 |
| Price Hint | 2 |
| Price To Book | 9.20881 |
| Price To Sales Trailing12 Months | 4.2937326 |
| Profit Margins | 0.0376 |
| Quick Ratio | 1.743 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | -0.085 |
| Regular Market Change Percent | -0.747253 |
| Regular Market Day High | 11.47 |
| Regular Market Day Low | 11.2066 |
| Regular Market Day Range | 11.2066 - 11.47 |
| Regular Market Open | 11.47 |
| Regular Market Previous Close | 11.375 |
| Regular Market Price | 11.29 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 88,468 |
| Return On Assets | 0.02707 |
| Return On Equity | 0.073649995 |
| Revenue Growth | 0.223 |
| Revenue Per Share | 2.606 |
| Sand P52 Week Change | 0.20204377 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 338,777,049 |
| Shares Percent Shares Out | 0.0007 |
| Shares Short | 244,900 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 297,140 |
| Short Name | Telix Pharmaceuticals Limited |
| Short Percent Of Float | 0.0008 |
| Short Ratio | 2.32 |
| Source Interval | 15 |
| State | VIC |
| Symbol | TLX |
| Target High Price | 22.139992 |
| Target Low Price | 20.008596 |
| Target Mean Price | 21.193222 |
| Target Median Price | 21.312151 |
| Total Cash | 251,910,000 |
| Total Cash Per Share | 0.741 |
| Total Debt | 579,860,992 |
| Total Revenue | 890,785,024 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 0.1 |
| Trailing P E | 112.9 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 9.3958 |
| Two Hundred Day Average Change | 1.8942003 |
| Two Hundred Day Average Change Percent | 0.20160076 |
| Type Disp | Equity |
| Volume | 88,468 |
| Website | https://telixpharma.com |
| Zip | 3,051 |